Cocrystal Pharma Inc (COCP)

$1.09 -0.03 (-2.68%)
Market Cap 15.44M
Revenue (ttm) 0.00
Net Income (ttm) -8.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 30,100
Avg Vol 64,452
Day's Range N/A - N/A
Shares Out 13.79M
Stochastic %K 68%
Beta 1.43
Analysts Strong Sell
Price Target $8.00

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 262 7123
Address:
19805 North Creek Parkway, Bothell, United States
bulmar
bulmar Aug. 17 at 9:36 PM
$COCP Frost is gonna have to come up with more money to pay all of his friends.
1 · Reply
focafoca99
focafoca99 Aug. 17 at 8:40 PM
$COCP elected Carol L. Brosgart, MD to its board of directors, disclosed in an 8-K filing.
1 · Reply
DOUG_Called_It
DOUG_Called_It Aug. 17 at 8:34 PM
$COCP added people to the board only to giveaway stock, sorry I mean your money
1 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 17 at 6:19 PM
$COCP 400k shorts still trying to hide Cocrystal got the funding no dilution shorts can't cover without running this up 100%+ shorts are toast example short squeezes like this are so p-a-i-n-f-u-l-l $WETO
1 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 17 at 5:38 PM
$COCP This will be one for the record books in the same league as Pharmacyclics 1.00 - $260 one of the greatest turn arounds ever $21 billion Abbvie with the only drug in the entire world for norovirus
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 17 at 4:53 PM
$COCP James Sapirstein, Chief Executive Officer of Cocrystal Pharma added, "I've had the privilege of knowing Carol since she was a key opinion leader during the HIV epidemic, working with her as a colleague at Gilead, and later having her join me at Tobira. Few people bring her combination of clinical rigor and real-world drug development experience, and I couldn't be more pleased to have her insight guiding Cocrystal at this pivotal stage."
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 17 at 4:49 PM
$COCP Strong Addition to the Board… read those tea leaves folks https://stocks.apple.com/AFNqq9ZbeQvOVP25eZu6dEQ
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 16 at 9:06 PM
$COCP 2-3 months and we’ll hopefully have strong Phase 1B clinical outcomes. if so, onto Phase 2 and thats when things can really get wild around here.. i think positive Phase 1B EOY results can push this to 5+
0 · Reply
uiua86
uiua86 Aug. 16 at 8:15 PM
$COCP I just start again to trade after 5 years, COCP gave me a very good exit point… I will never forget you 🫶🏼😘
0 · Reply
elon_musk22
elon_musk22 Aug. 15 at 3:50 PM
$COCP this is the other partner in crime with "12 shares" had to brag 6 yrs ago now cries every single day except doesn't blame himself for not selling a covid stock these clowns since the mkt is guaranteed returns lets go baby! lmfao
0 · Reply
Latest News on COCP
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Aug 17, 2026, 11:17 AM EDT - 17 hours ago

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Cocrystal Pharma announces $5M investment from Opko Health

2026-08-03T11:25:21.000Z - 14 days ago

Cocrystal Pharma announces $5M investment from Opko Health

OPK

Cocrystal Pharma announces $5M private placement with Opko Health

2026-08-03T11:15:31.000Z - 14 days ago

Cocrystal Pharma announces $5M private placement with Opko Health

OPK

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Aug 3, 2026, 7:00 AM EDT - 14 days ago

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds

2026-06-03T11:14:05.000Z - 2 months ago

Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Jun 3, 2026, 7:00 AM EDT - 2 months ago

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses

2026-05-26T12:20:21.000Z - 2 months ago

Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

May 26, 2026, 8:00 AM EDT - 2 months ago

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026, 8:00 AM EDT - 3 months ago

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Apr 30, 2026, 4:05 PM EDT - 3 months ago

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Cocrystal Pharma files $150M mixed securities shelf

2026-04-23T23:25:20.000Z - 4 months ago

Cocrystal Pharma files $150M mixed securities shelf

Cocrystal Pharma receives FDA Fast Track designation for CDI-988

2026-04-02T12:22:27.000Z - 4 months ago

Cocrystal Pharma receives FDA Fast Track designation for CDI-988

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 31, 2026, 8:00 AM EDT - 4 months ago

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma announces first subjects dosed in Phase 1b study of CDI-988

2026-03-09T12:10:09.000Z - 5 months ago

Cocrystal Pharma announces first subjects dosed in Phase 1b study of CDI-988

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Mar 9, 2026, 8:00 AM EDT - 5 months ago

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Feb 19, 2026, 8:00 AM EST - 6 months ago

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Cocrystal Pharma receives IRB approval from Emory University for Phase 1b trial

2025-12-18T13:16:41.000Z - 8 months ago

Cocrystal Pharma receives IRB approval from Emory University for Phase 1b trial

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Dec 18, 2025, 8:00 AM EST - 8 months ago

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Dec 1, 2025, 8:00 AM EST - 9 months ago

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year

2025-11-14T13:11:15.000Z - 9 months ago

Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Nov 14, 2025, 8:00 AM EST - 9 months ago

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma completes $1.03M private placement

2025-10-30T12:26:32.000Z - 10 months ago

Cocrystal Pharma completes $1.03M private placement

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma receives NIH SBIR award to advance influenza inhibitor program

2025-10-27T12:20:43.000Z - 10 months ago

Cocrystal Pharma receives NIH SBIR award to advance influenza inhibitor program

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Oct 2, 2025, 8:00 AM EDT - 11 months ago

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Cocrystal Pharma files to sell 5.74M shares of common stock for holders

2025-09-19T20:35:11.000Z - 11 months ago

Cocrystal Pharma files to sell 5.74M shares of common stock for holders

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 15, 2025, 4:30 PM EDT - 1 year ago

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Cocrystal Pharma announces up to $13M registered direct offering

2025-09-12T13:45:10.000Z - 1 year ago

Cocrystal Pharma announces up to $13M registered direct offering

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 12, 2025, 9:43 AM EDT - 1 year ago

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Cocrystal Pharma showcases CDI-988, antiviral for norovirus infection

2025-09-12T12:10:38.000Z - 1 year ago

Cocrystal Pharma showcases CDI-988, antiviral for norovirus infection

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Sep 12, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Cocrystal Pharma receives IND clearance for challenge study of CDI-988

2025-09-08T12:05:24.000Z - 1 year ago

Cocrystal Pharma receives IND clearance for challenge study of CDI-988

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Cocrystal Pharma reports Q2 EPS (20c), consensus (30c)

2025-08-14T12:15:44.000Z - 1 year ago

Cocrystal Pharma reports Q2 EPS (20c), consensus (30c)

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma presents Phase 1 results for CDI-988

2025-08-05T12:26:50.000Z - 1 year ago

Cocrystal Pharma presents Phase 1 results for CDI-988

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Jul 10, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Cocrystal Pharma price target lowered to $6 from $7 at H.C. Wainwright

2025-06-20T10:10:30.000Z - 1 year ago

Cocrystal Pharma price target lowered to $6 from $7 at H.C. Wainwright

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

Cocrystal announces CC-42344 active against 204 Texas H5N1 avian influenza

2025-05-29T12:10:22.000Z - 1 year ago

Cocrystal announces CC-42344 active against 204 Texas H5N1 avian influenza

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 29, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 15, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Mar 6, 2025, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 19, 2024, 4:05 PM EDT - 2 years ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Aug 15, 2024, 3:00 PM EDT - 2 years ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 13, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

May 1, 2024, 8:00 AM EDT - 2 years ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Mar 5, 2024, 8:30 AM EST - 2 years ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Dec 6, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 29, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 27, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 9, 2023, 8:00 AM EST - 3 years ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Oct 31, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 10, 2023, 8:30 AM EDT - 3 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 26, 2023, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Jan 23, 2023, 9:00 AM EST - 3 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

bulmar
bulmar Aug. 17 at 9:36 PM
$COCP Frost is gonna have to come up with more money to pay all of his friends.
1 · Reply
focafoca99
focafoca99 Aug. 17 at 8:40 PM
$COCP elected Carol L. Brosgart, MD to its board of directors, disclosed in an 8-K filing.
1 · Reply
DOUG_Called_It
DOUG_Called_It Aug. 17 at 8:34 PM
$COCP added people to the board only to giveaway stock, sorry I mean your money
1 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 17 at 6:19 PM
$COCP 400k shorts still trying to hide Cocrystal got the funding no dilution shorts can't cover without running this up 100%+ shorts are toast example short squeezes like this are so p-a-i-n-f-u-l-l $WETO
1 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 17 at 5:38 PM
$COCP This will be one for the record books in the same league as Pharmacyclics 1.00 - $260 one of the greatest turn arounds ever $21 billion Abbvie with the only drug in the entire world for norovirus
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 17 at 4:53 PM
$COCP James Sapirstein, Chief Executive Officer of Cocrystal Pharma added, "I've had the privilege of knowing Carol since she was a key opinion leader during the HIV epidemic, working with her as a colleague at Gilead, and later having her join me at Tobira. Few people bring her combination of clinical rigor and real-world drug development experience, and I couldn't be more pleased to have her insight guiding Cocrystal at this pivotal stage."
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 17 at 4:49 PM
$COCP Strong Addition to the Board… read those tea leaves folks https://stocks.apple.com/AFNqq9ZbeQvOVP25eZu6dEQ
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 16 at 9:06 PM
$COCP 2-3 months and we’ll hopefully have strong Phase 1B clinical outcomes. if so, onto Phase 2 and thats when things can really get wild around here.. i think positive Phase 1B EOY results can push this to 5+
0 · Reply
uiua86
uiua86 Aug. 16 at 8:15 PM
$COCP I just start again to trade after 5 years, COCP gave me a very good exit point… I will never forget you 🫶🏼😘
0 · Reply
elon_musk22
elon_musk22 Aug. 15 at 3:50 PM
$COCP this is the other partner in crime with "12 shares" had to brag 6 yrs ago now cries every single day except doesn't blame himself for not selling a covid stock these clowns since the mkt is guaranteed returns lets go baby! lmfao
0 · Reply
elon_musk22
elon_musk22 Aug. 15 at 2:48 PM
$COCP stock queen 👸 owns "12 shares" he said it 12 shares = $13.44 delete your account stay away from mkt total embarrasment
0 · Reply
StockKiiNG
StockKiiNG Aug. 13 at 7:06 PM
$COCP run as far as you can from this stock…unless you are shorting it.😂 October 10, 2022: A 1-for-12 reverse stock split. This consolidated every 12 existing shares into 1 single share to maintain compliance with Nasdaq's minimum bid price rules. January 23, 2018: A 1-for-30 reverse stock split. This occurred right around the timeframe the company was preparing for its primary Nasdaq uplisting. March 14, 2011: A 10-for-1 forward stock split. This split took place under the early predecessor entity (BioZone Pharmaceuticals).
1 · Reply
DaphneBrooke
DaphneBrooke Aug. 13 at 1:53 PM
$COCP Finished buying yesterday because I ran out of money. LOL
0 · Reply
Ultimate1trader
Ultimate1trader Aug. 11 at 2:23 PM
$COCP nice start, now we need NEWS
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 10 at 10:31 PM
$COCP being played with like any other spec stock.. of the analysts covering the stock, one in particular is very well rated and his price target is 9.00
0 · Reply
Ultimate1trader
Ultimate1trader Aug. 10 at 9:31 PM
$COCP somthing is cooking
1 · Reply
BULLSWIN75
BULLSWIN75 Aug. 10 at 7:07 PM
$COCP Public Float: Approximately 10.26 million shares. imagine how quickly this will run on strong clinical findings. If strong, wouldnt surprise anyone if Pfizer or some large pharma/Biotech comes in and buys out COCP.
1 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 10 at 4:43 PM
$COCP At least 10+ is fair this is but what nobody gets since this is not widely followed it is really 1b/2a study (just less people) BUT proof of concept challenge study in humans so stock will explode once this proves it works in humans to prevent norovirus virus
1 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 10 at 3:12 PM
$COCP $50 on the data or a month or two later there is no other drug for norovirus
1 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 10 at 3:08 PM
$COCP FYI Short Squeeze can happen at any time mkt hours or after hours no shares available private was done with unregistered shares so about 500k to buy in mkt much higher from here
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 10 at 3:06 PM
$COCP I’m in… near term results for CDI-988 drug candidate look very promising ✅ New CEO has launched over 20 drugs ✅ Current price is excellent entry point ✅
1 · Reply
tymtested
tymtested Aug. 8 at 6:59 PM
$COCP price target should probably be $80 with regard to this new discovery COCP made !
2 · Reply